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JANAE CULMER
(Under the Direction of James Carter)
ABSTRACT

The lack of approved vaccines, medications and treatment regimens has significantly contributed to the
rapid spread of mosquito-borne viruses such as Dengue and Zika virus. The complex immunopathology
of these viruses presents limitations for the development and implementation of a definitive, safe and
effective approach to combat infections. Previous research has demonstrated that vector control strategies
such as the elimination of larval habitats, larviciding with insecticides, the use of biological agents and the
application of adulticides have been unsuccessful in the reduction of viral transmission leading to the
need for the continued development of antivirals. This research proposes an approach for a drug delivery
system that involves novel antivirals that suppress dengue virus in an intracellular pH specific manner
with the use of micellar nanoparticles. Drug-loaded nanoparticle that dissociates when exposed to a pH of
6.0, will release drug at the targeted location in the cell, in particular, the proximal trans-Golgi network in
the cell. Three (3) novel pyridazine derivatives were analyzed and possessed anti-viral activity against
Zika virus through the use of cell-culture based suppression techniques. The derivatives described in this
thesis will be designed and analyzed for its future potential in drug encapsulation into newly synthesized
mPEG-PLA comprised micellar nanoparticles.
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CHAPTER 1
INTRODUCTION
1.1 The Field of Virology
Virology is an extremely broad topic which focuses on subjects such as biology, animal
welfare, agriculture and ecology.1 It is a branch of science that studies viruses and virus-like
organisms including their detection, classification, structure, life cycle, isolation, replication,
disease-producing properties, cultivation and their use in research and therapies.1 The main
motivation for the study of viruses is due to the myriad number of diseases they cause. Common
diseases that viruses are responsible for include: HIV/AIDS, chickenpox, herpes, mumps,
measles, shingles, the common cold and flu and Coronavirus disease. It is through virology that
scientists can recognize, investigate, and diagnose viral infections along with establishing
relationships between the virus, antiviral drugs and the pharmacological responses produced.1
Two scientists, Dmitri Ivanovsky and Martinus Beijerinck are credited for their contribution
to the discovery of the virus.2 In 1982, Ivanovsky was investigating a disease in tobacco plants
known as the Tobacco Mosaic Disease. It was known by this name due to the transformation of
green tobacco leaves to discolored leaves with a mosaic-like pattern.2 Ivanovsky knew that this
incident was caused by a small infectious agent which was not bacteria. Six years later,
Beijerinck carried out similar experiments on tobacco plants and named the “small infectious
agent”, a virus.
A virus is an infectious microbe that consists of a segment of genetic material surrounded by
a bilayer protein coat (Figure 1). Viral genomes are very diverse, as they may contain DNA or
RNA, be single or double-stranded, linear, circular, and be various lengths.3 A virus cannot
replicate alone. Instead, it must infect cells and use components of the host cell to make copies of
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itself. Most times, a virus kills the host cell in the process, causing damage to the host organism.3
Viruses have short generation times and relatively high mutation rates.4 This elevated mutation
rate is what allows viruses to rapidly adapt to changes in their host environment. The lack of
proofreading skills in the RNA polymerase, which is responsible for copying the virus’s genes
contributes to this. Viruses can infect all forms of living organisms including animals, plants
fungi, bacteria and archaea.
Viruses are categorized at several hierarchical levels of order, family, subfamily, genus,
and species based on shared characteristics. There are currently more than 3,600 species, 164
genera, and 71 families comprised of more than 30,000 distinct viral isolates.3,4 Viruses are
divided into families according to their size, shape, chemical makeup, genomic structure, and
method of replication.4
1.2 Overview of Flaviviridae
The name Flaviviridae, which means "yellow" in Latin, honors the yellow fever virus, which
was discovered in Cuba.5 The members of this virus family, which was composed primarily of
positive-stranded RNA viruses,
were grouped into the Flavivirus,
Pestivirus, and Hepacivirus
superfamilies. Flaviviridae are
classified according to a small
number of fundamental similarities
Figure 1: Typical Flavivirus virus diagram showing the exterior
protein layer encasing the viral RNA5

in viral particle properties and
replication life cycle. They are

distinguished by a lipid bilayer that encases the nucleocapsid in two or more subunits of the
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envelope (E) glycoprotein. The single-stranded RNA genome complex of the nucleocapsid is
made up of several basic capsid (C) proteins. (Figure 1).5
Receptor-mediated endocytosis is the
first step in the general replication of the
Flaviviridae family of viruses. The virus
fuses with the endosomal membrane and
releases itself into the cytoplasm. It then
breaks apart releasing the viral genome.
Viral RNA is translated into a single
polypeptide and then replicated. Virus
assembly occurs on the surface of the

Figure 2: Life cycle of the Flaviviridae family of viruses7

endoplasmic reticulum and newly
synthesized RNA buds out. Immature viral particles are then transported through the trans-Golgi
network where they mature and convert to their infectious form. Mature viruses will then go on
to infect other cells. 6 Figure 2 showcases the replication pathway of Flaviviridae viruses.
There are more than 50 species of viruses in the Flavivirus genus of the Flaviviridae family,
the majority of which are arthropod-borne human infections.1,5 The infectious particles typically
have a shape that is nearly spherical and have a diameter of about 50 nm.5 The family of viruses
includes pathogens that cause hepatitis, encephalitis, flaccid paralysis, microcephaly, and
vascular leakage. This family of viruses is also responsible for mosquito-transmitted diseases
such as Yellow Fever, Dengue Fever, Japanese encephalitis, West Nile viruses, and Zika virus.7
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1.3 Dengue and Zika Viruses
Dengue and Zika viruses are closely related members of the flavivirus genus and are both
transmitted to humans via the bites of infected mosquitoes.9 These viruses have 40% homology
within the envelope protein. Dengue virus infection can be asymptomatic or can cause symptoms
such as fever, headache, muscle aches, and rash.10 Severe symptoms include hemorrhagic fever
and internal bleeding.10 Dengue has become quite prevalent in the United States as the CDC
reported dengue as a notifiable condition in 2010. Recent outbreaks of dengue in the United
States in Florida, Texas and Hawaii have been noted to be sources of local spreading of this
disease marking the fact that this is no longer a travel-associated
disease. 11 Outbreaks are often characterized by factors such as weather and lifestyle patterns.
Zika virus causes mostly mild disease with symptoms such as fever, rash, and joint pain
that typically resolves within a week.12 If infected with Zika, severe conditions that can develop
include Guillain-Barré syndrome, an autoimmune condition affecting the peripheral nerves, and
microcephaly in pregnant women where the virus can lead to brain defects in the developing
fetus including microcephaly.13 With a vast portion of the population at risk and symptoms that
can seamlessly go unnoticed, the need for targeted therapies is quite clear.
1.4 Aedes Mosquitoes
Aedes albopictus and Aedes aegypti are two mosquito species that frequently serve as the
primary vectors for Flaviviridae viral illnesses such as Dengue and Zika. These vectors live in
tropical, subtropical, and temperate climates.8 It is only the female mosquito that is responsible
for biting therefore they are also responsible for the transmittance of the virus to the host. The
Aedes albopictus mosquito blood feed on both animals and humans which drops the likelihood of
spreading viruses transmittable to humans. The Aedes aegypti prefer to feed on human blood,
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making them more likely to spread diseases like dengue, West Nile, and Zika that are transmitted
by people. The Zika virus is not currently being transmitted locally in the United States. The last
instances of regional mosquito-borne Zika transmission in the continental United States were in
Florida and Texas in 2016–17, according to the Centers for Disease Control and Prevention.
Local dengue epidemics have most recently been reported in Hawaii (2015), Florida (2013,
2020), and Texas in the United States (2013). The majority of outbreaks in the United States
have been localized to modestly sized locations.8 Figure 3 shows the CDC’s best estimate of the
potential range of Aedes aegypti and Aedes albopictus in the contiguous United States.

Figure 3: Map representing the potential range of Aedes aegypti and Aedes albopictus in the US9

1.5 Virus Suppression Methods, Treatments and Vaccines
Vaccines are considered the most effective method for the prevention of virus infection.
The process of creating vaccines and antiviral medications may be considered challenging due to
the fast capability of a virus to evolve and frequent resistant mutations. Zika currently lacks an
approved vaccine whereas Dengue has one known vaccine, Dengvaxia. To formulate this
vaccine, the precursor membrane and envelope found in the yellow fever virus were swapped out
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for dengue counterparts.14 The four dengue strains are not all protected by this vaccine.
Dengvaxia showcases 34.7% efficiency against DENV2. This strand produces the most serious
infection compared to the other strands. Use of this vaccine is only approved for individuals
between the ages of 9 to 16 that have had a history of the dengue infection.13 This leaves others
out of this age category at greater risk for fighting off infections of Dengue. Furthermore, given
that one research resulted in the deaths of 10 infants, vaccine developers have expressed worries
about the efficacy and safety of the vaccine.15 Following the establishment of virus immunization
programs, escape mutants could possibly appear.
Dengue and Zika viruses can simultaneously replicate in the same mosquito populations.
The cocirculation of these viruses produces a phenomenon that leads to simultaneous infections
of individuals and cross-immunoreactivity of related antibodies.16,17 The infectivity of one virus
enhances the subsequent infection of the other virus which raises awareness for the necessity of
vaccines and antiviral medications. The above-mentioned advantages and disadvantages show
how urgently small molecule inhibitors and medication delivery systems against viruses need to
be developed. As a result, the research that is being presented here is intended to meet these
needs.
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CHAPTER 2
NOVEL PYRIDAZINE DERIVATIVES
2.1 Antiviral Drugs
Antivirals are drugs that help the body fight against dangerous viruses. Antiviral drugs
protect organisms from viral infections and the spread of those diseases by taking preventive
measures.18 Its functionality is entirely dependent on the elements of the medicine from which it
is made and the virus that it is intended to combat. Antivirals primarily work in three different
ways: 1) Disabling receptors prevents the virus from attaching to and infecting healthy living
cells. 2) Boosting the immune system enables the organism to fend off viral activity. 3) Reducing
the amount of active virus in the organism.18
Important variables affecting the frequency and/or severity of viral infections include
population density, immunological health, infection vectors and virulence, nutritional condition,
cleanliness, genetic vulnerability, and medical management of cases.19 Thus, the frequency of
virus infections, their clinical significance, and the requirement for antiviral medications vary
from location to location and from time to time. The availability, safety, cost, and efficacy of
alternative approaches, such as the control of infection-carrying vectors, viral vaccine
vaccination, or therapy with already-approved antiviral medications, should be considered when
developing new antiviral medications.20 Pyridazine derivative compounds have been shown to
showcase antiviral properties.
2.2 Novel Small Molecule Pyridazines
Pyridazines and their derivatives have recently attracted a lot of interest due to the
discovery of compounds with potential medical applications.21 Pyridazines are heteroaromatic,
six-membered chemical compounds having a wide range of biological and pharmacological
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activity. They play a key structural role in many physiologically active molecules. The
pyridazine ring system is a 1, 2- diazine or o- diaza benzene.21 The diazo group provides
significant use as precursors for reactive intermediates.21
Due to its imine functional groups, it is an odorless liquid
at ambient temperature with a comparatively high boiling
point of 208 °C and low melting point of -8 °C. The
pyridazine molecule is a pyridine-like heteroaromatic
Figure 4: Structure for pyridazine

substance. Pyridazine’s fundamental aromatic ring
21

structure consists of two nearby nitrogen atoms (Figure 4).
This compound's nitrogen atoms provide special chemistry; they can interact with
suitable substrates that have acidic functional groups to produce supramolecular complexes.
Additionally, pyridazines have high-efficiency turnover numbers and are efficient water
oxidation catalysts.21,22 Although pyridazines are not used in everyday life, they are primarily
used in research and industry as a component of many complex chemical compounds. In
addition, pyridazines are helpful intermediates in physical organic chemistry for the synthesis of
numerous other heterocycles.23
Pyridazines have been found to have a wide range of biological effects, including those
that are antibacterial, antibiotic, anti-depressant, anti-diabetic, anti-hypertensive, analgesic, antitumor, antiviral, anti-inflammatory, anti-viral, anti-cancer, anti-aggregative, and anti-epileptic.
These substances are also used to induce drowsiness, hypnosis, anesthesia, sleep, and muscular
relaxation in order to treat sleep problems like insomnia.24
Pyridazines are widely used in medication development and interfere with a variety of
enzyme regulatory pathways. Due to their structure, stability, and reactivity as well as their
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propensity to produce stable compounds with beneficial biological properties, some recently
synthesized pyridazine derivatives have found interest in a variety of scientific domains.
According to recent studies, dry eye problems, prostate cancer, and dermatosis can all be treated
with pyridazine derivatives.24 Additionally, pyridazines have the ability to conduct electricity.
These substances have qualities including low density, good resistance at room temperature, and
the ability to be stretched to create thin films. These conductive polymers can also be
incorporated into nanoparticles.25
2.3 Pyridazine Derivatives: PY-LP-3, PY-LP-6 and PY-LP-12
Three (3) novel small molecule microwave-assisted pyridazine derivatives were
synthesized from the lab of Dr. Shainaz Landge. The derivatives have similar structures and
differ in the phenyl substituent. These positionings give us useful information on the binding
position while allowing us to experiment with the system's electronics. It will also direct us as to
which group should be given preference for electronic donations and withdrawals in order for the
system to function. The pyridazine derivatives are shown and described below:
Derivative PY-LP-3 has a chemical name of 3(5,6-diphenylpyridazin-3-yl) with a chemical formula of
C22H17N3 and a molecular weight of 323.40 g/mol. The
functional group belonging to this derivative is the amino
group, -NH2, which is meta-positioned on a benzene ring
(Figure 5) . Consisting of a phenyl group attached to an
amino group, aniline is formed. By itself it is the
simplest aromatic amine. When stable, aniline is
mainly used for the preparation of analgesics,

Figure 5: Structure of Pyridazine Derivative,
PY-LP-3 with emphasis placed on the metapositioned amino functional group
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antipyretics, antiallergics, and vitamins.26 Examples of known drugs that contain aminobenzene
are sulfamethizole which is an antibiotic used to treat a wide variety of susceptible bacterial
infections, sulfadoxine which is a long-acting sulfonamide used for the treatment or prevention
of malaria and bicalutamide which is used as a receptor inhibitor to treat Stage D2 metastatic
carcinoma of the prostrate.27
PY-LP-6 has a chemical name of 5-(4-chlorophenyl)-3,4-diphenylpyridazine
with a chemical formula of C22H15ClN2 and a molecular weight of 342.83 g/mol. The functional
group belonging to this derivative is the chloro group, -Cl,
which is para-positioned on a benzene ring. The reactivity of
chlorobenzene is low when compared to other para directors
attached to benzene rings. This is due to the high
electronegativity of the chlorine atom. It is electron
withdrawing so reduces the electron density of the ring. In the
pharmaceutical industry, chlorobenzene is used in the

Figure 6: Structure of Pyridazine
Derivative, PY-LP-6 with emphasis
placed on the para-positioned chloro
functional group

synthesis of vitamin B6 and in the synthesis of drugs for epilepsy, thyroid and liver cancer.28
Derivative PY-LP-12 has a chemical name of 6-(4-methoxyphenyl)-3,4diphenylpyridazine with a chemical formula of C23H18N2O and a
molecular weight of 338.41 g/mol. The functional group
belonging to this derivative is the methoxy group, -OCH3, which
is para-positioned on a benzene ring. Methoxy is also considered
an electron withdrawing group due to the electronegativity of
oxygen. The functional group itself is included in many
helpful drugs. These include: methoxyflurane which is used to

Figure 7: Structure of Pyridazine
Derivative, PY-LP-12 with emphasis
placed on the para-positioned methoxy
functional group
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ease pain and methoxy polyethylene glycol-epoetin which is an injection used to treat anemia
and chronic kidney failure.29
All the pyridazine derivatives underwent initial cell culture-based suppression assays,
dose dependent assays and viral titration via plaque assay. Those showcasing viral suppression
will then be drug loaded into mPEG-PLA nanoparticles. Due to a production shortage of these
derivatives, drug-loading was not executed. Upon gaining further supply of these derivatives,
drug-loading is in future perspective.
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CHAPTER 3
MICELLAR NANOPARTICLES
3.1 Biodegradable pH Responsive Coblock Polymers
Due to their numerous uses, biodegradable polymers have recently attracted attention for
usage in biological applications. Biocompatible polymers may now be assembled into functional
nano-sized units thanks to special characteristics, expanding their therapeutic applications. These
biodegradable polymers are advantageous for biomedical applications because they are quickly
broken down, absorbed, or removed in a human body after serving their purpose.30
Drug formulation uses biodegradable co-block polymers in a variety of ways.
Biocompatible monomers that are deliberately chosen for beneficial qualities, such as medication
solubility and dissociation, are combined by scientists. Since amphiphilic block copolymers have
been recognized to self-assemble to create polymeric micelles under particular concentrations,
they combine into copolymers and enable researchers to investigate their biological applications,
including drug delivery systems. In relation to my research, proposed micellar nanoparticles and
related antivirals will help in identifying pH-microenvironments within infected cells that can aid
in drug delivery leading to a novel method for the suppression of viruses.
3.2 Diblock mPEG-PLA Polymer
A and B are the two types of monomers that make up a diblock copolymer, a polymer.
When two monomer chains are grafted together to make a single copolymer chain, the
monomers are ordered so that each monomer has its own chain.31 Methoxypolyethylene glycol
(mPEG) and polylactide are the two segments that are connected to produce the single diblock
strand that gives the polymer chain, mPEG-PLA, its name. Polymer segment patterns are
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frequently shortened to alphabetic patterns that give each individual monomer unit a letter. The
designated letters for the mPEG-PLA polymer would be "AB" (Figure 8). The "A" units in this
case relate to the mPEG that caps the polylactide "B" unit. The A monomer coupled to the B
monomer forms the diblock, mPEG-PLA.

Figure 8: Schematic illustration depicting the formation of a biodegradable AB diblock co-polymer

Figure 9: AB diblock formation via ring-opening polymerization of D,L-lactide and
methoxypolyethylene glycol32

By employing mPEG as an initiator and stannous octoate [Sn(Oct)2] as a catalyst, ringopening polymerization of D,L-lactide results in the polymerization of the AB diblock (Figure
9). Methoxypolyethylene glycol and polylactide are two specific polymers that are utilized in
numerous medicines and are listed in the FDA's criteria for commercially available inactive
components.32 The created diblock, mPEG-PLA, has a special ability to undergo thermally
induced self-assembly without the need of harsh solvents. The solvent can stay biocompatible
and pH-specific by carefully lining up under unique heating conditions, allowing the polymer to
target the acid-catalyzed fusion of the virus and endosome where viral RNA is released and
started for replication in the endoplasmic reticulum. The AB diblock polymer is attractive as a
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potential medication delivery method because of its beneficial biodegradable and nontoxic
qualities.33
3.3 Assembly and Characterization of mPEG-PLA Micelles
Amphiphilic characteristics are present in mPEG-PLA copolymer as it contains both
hydrophobic and hydrophilic regions. When micelles form in a solution, the hydrophilic mPEG
chain segment forms the outer micelles, and the hydrophobic PLA chain segment forms the inner
micelles.34 Due to self-assembly into polymeric micelles in an aqueous solution, this property of
copolymer materials can be utilized to boost the solubility of some insoluble pharmaceuticals.34,
35

Thermally induced self-assembly forms spherical shells that can be used as carriers when the

polymer is exposed to a sudden change in temperature (Figure 10). In a biologically friendly
solvent, such as ultra-pure water, these micelles
can be formed.
Prepared mPEG-PLA nanoparticles
should be spherical in shape with a size less than
100 nm.36 Surface charge and surface chemistry
and size distribution are all investigated by
dynamic light scattering and Zeta-potential
analyzer.

Figure 10: AB diblock polymer based, drugloaded micelles36
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CHAPTER 4
CELL CULTURE BASED SUPPRESSION
4.1 Vero Cell Line

Derived from the kidney of an African green monkey (Cercopithecus aethiops) in
the1960s, Vero cells are among the most widely used mammalian cell lines in science,
particularly in virology experiments. 37 They are anchorage-dependent cells as they are unable to
divide or survive without being affixed to a
surface. Lacking the ability to make interferon
alpha or beta due to a loss in type I interferon
genes, they have increased susceptibility to
viral infection. Numerous viruses, including
the simian polyoma virus SV-40, measles,
rubella, arboviruses, adenoviruses, influenza
virus, and Ebola hemorrhagic fever virus have

Figure 11: Microscopic Image of Vero Cells under
Green Light at 100-fold magnification38

been studied using Vero cells.38

Vero cells have the following advantages. Firstly, the cell bank is easy to establish and
preserve, at the same time it can be continuously passaged with a fast growth rate. Secondly,
Vero cells have stable genetic traits and a low probability of malignancy. Thirdly, Vero cells are
sensitive to a variety of viruses and have high virus titers.39 Finally, Vero cells could exceedingly
be resistant to various cultural conditions, and the requirements are not high that it can grow well
on the surface of the microcarrier, which proves that Vero cells have significant value in the
development of a series of viral vaccines. 39
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4.2 Dose Dependence Assay
Dose-response assays are a popular and often used technique that evaluates the toxicity of
prospective drug targets on cell test populations.40 These tests often entail applying successive
dilutions of the test substances such as drug to cell samples in order to assess the level of cell
activity over a wide range of doses.
An effective dose is predicated on the ideas of IC50 and EC50. The pharmacological
concentration at which half-maximal reaction occurs is known as the EC50. The inhibitory
concentration (IC50) is the level at which the response (or binding) is reduced by 50%.
The most generally used and useful indicator of a drug's effectiveness is its half-maximal
inhibitory concentration (IC50). It provides a gauge of the potency of an drug in pharmacological
research by indicating the amount of drug required to block a biological process by 50%. As a
toxicity gauge, EC50 is used.41 Calculations of IC50 and EC50 are possible after quantitation by
plaque reduction assay.

4.3 Plaque Reduction Assay
A trusted technique for determining viral concentration in relation to infectious dose is
the plaque assay. To perform the assay, a monolayer of virus-infected cells must be counted to
determine how many plaque forming units (pfu) were generated. Crystal violet staining of the
preserved cell monolayer allows for the visualization of plaques.42
Cultured cells that can be infected by the target virus are needed for plaque assays. After
being seeded onto a surface that will allow them to adhere and develop, the cells are permitted to
form a confluent monolayer. The next step involves diluting a viral sample numerous times
before adding it to a 24-well plate containing cells. Infected cells that are killed by the virus
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separate and break the monolayer through lysis or other processes. On the growing surface, these
areas—which are now empty of cells—appear as round spots and are referred to as plaques.
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CHAPTER 5
MATERIAL AND METHODS
5.1 Synthesis of Novel Pyridazine Derivatives
A total of three (3) organic compounds were previously synthesized for the purpose of
this research project via collaboration with Dr. Shainaz Landge. The microwave assisted
synthesis of these derivatives first began with the synthesis of ionic liquid, 1-n-octyl-3,5dimethylpridinium bromide. Its preparation consisted of two reagents, n-octyl bromide and 3,5lutidine (Table 2). Once mixed, continuous stirring took place for a total of twenty (20) hours in
a dark environment until a yellow liquid has been formed. Vacuum filtration was also carried out
and the ionic liquid was stored in a desiccator until use.
CHEMICAL

MOLECULAR

MOLARITY

WEIGHT (g)

MASS

VOLUME

DENSITY

(g)

(mL)

(g/L)

EQUIVALENCE

107.15

0.1

10.715

11.41

0.939

1

193.128

0.1

19.312

17.34

1.114

1

n-octyl bromide

8

3,5-lutidine

Table 1: Reagents and the amounts utilized to synthesis 1-n-octyl-3,5-dimethylypridinium, ionic liquid
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In order to synthesize each of the pyridazine derivatives (Table 3), five reagents were
used in various quantities each unique to each derivative. These reagents consisted of benzil,
acetophenone (methyl, amino, chloro, or fluro), hydrazine hydrate, 4-tetra-butyl ammonium,
prepared ionic liquid and ethanol to dissolve solids. Once combined, the mixture was stirred
overnight in a round bottom flask completely covered with foil to prevent light from interfering
with the reaction. After stirring, cold DI water was added to precipitate the reaction.
Characterization via Nuclear Magnetic Resonance (NMR) was completed to confirm that the
compounds had cyclized. Once cyclized, purification was done through column chromatography
techniques. As previously stated, synthesis of novel pyridazines derivates were prepared via a
collaborator therefore, this research does not give details regarding its characterization and
optimization.
Chemical Name
PY-LP-3

3-(5,6-diphenylpyridazin-3-yl)aniline

PY-LP-6

5-(4-chlorophenyl)-3,4-diphenylpyridazine

PY-LP-12

6-(4-methoxyphenyl)-3,4-diphenylpyridazine

Table 2: Pyridazine Derivatives along with their chemical names and structures

Structure
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5.2 Dose Dependance Assay
Pyridazine derivatives products PY-LP-3, PY-LP-6 and PY-LP-12 were used for analysis
of cell culture-based suppression. 0.11g -0.12g of each drug was dissolved in dimethylsulfoxide
(DMSO) and then transferred to a 50 mL conical flask. Dulbecco’s Modified Eagle Medium
(DMEM) containing 10% Fetal Bovine Serum (FBS) was also added to the 50 mL mark. The
working concentration of PY-LP-3, LY-LP-6

Drug
alone
(Control)

Virus
+
Media
(Control)

and PY-LP-12 were calculated to be,
Drug Conc.
+
Virus

respectfully: 33.3 mg/mL, 27.6 mg/mL and 27.5
mg/mL. In 6 well plates, Vero cells were plated

Drug Conc.
+
Virus

Drug Conc.
+
Virus

Drug Conc.
+
Virus

and left to incubate for a total of 24 hours to
allow for cell bonding to well surface.
Following this incubation period, a dose-

Figure 12: Schematic diagram of a 6-well cell
culture plate that showcases placement of control
sample and samples containing various
concentrations of drug.

dependent assay was performed. Using a 2
mL aspirating pipette, media was aspirated

from the wells. The cells were then washed twice with 0.5 mL of Phosphate Buffered Saline
(PBS) with aspiration between washes. The cells were then overlayed with 0.5 mL DMEM
containing 2% FBS, which possessed 50 μL of Zika virus. Zika virus was used in the testing of
potential suppression by the pyridazine derivatives due to initial issues growing dengue virus
stocks. We suspect this is due to suspect samples that were obtained from the American Type
Culture Collection (ATCC), a global biological resource center that collects, stores and
distributes microorganisms, cell lines and other research material. The appropriate amount of
drug and virus were added into the wells except for the negative control and drug only wells
(Figure 13). The 6 well plates were placed in 37 degrees Celsius, 5% CO2 incubator for 1 hour
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whilst being rocked/tilted every 15 minutes. After the hour, media was aspirated from the wells
and the respective contents were added back into each well excluding the addition of virus. The
cell plate was then incubated for two days. After the incubation period, the cell culture fluids
were collected and stored at -80 degrees Celsius for future analysis by plaque assay. This same
procedure was also utilized for the addition of nanoparticles/micelles against virus.
5.3 Virus Titration Using Plaque Reduction Assay

Figure 13: Schematic diagram of a serial dilution plan for plaque assay

First, virus titration consisted of setting up serial dilutions from the cell culture fluid
stocks that were previously collected and stored from the dose-dependent assay. Ten fold serial
dilutions was the method used to make these dilutions, with each microtube containing 450 μl of
DMEM (Figure 14). Using a pipette, 50 μl of virus sample from the stock was placed in the first
microtube, labeled 10-1 and vortexed for ~3 seconds. From the microtube labeled 10-1, 50 μl of
that sample was transferred into the second microtube, labeled 10-2 and vortexed. This process
was then repeated for the remaining dilutions, 10-3 to 10-6 as seen in Figure 15 . To avoid cross
contamination, pipette tips were changed between dilutions. The day prior to the assay, Vero
cells were plated in a 24-well plate to prepare for the addition of the samples containing the
serial dilutions. Each column of the plate was aspirated of its media and the samples from the
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microtube were gently added in each respectively well. The cells were then incubated at 37oC for
5 days.
A)

B)

10-1

10-2

10-3

10-4

10-5

10-6
10-1

10-2

10-3

10-4

10-5

10-6

Figure 14: Schematic representation of 10-fold serial dilution samples dilutions from respective wells of
6-well plates (Panel A) into 24 well plates (Panel B)

After the 5 day incubation period, the wells were aspirated and 0.05% crystal violet in 10%
formalin was added fix and stain cells. The plate was then incubated for 30 minutes at room
temperature and crystal violet staining solution was removed via aspiration. The cells were then
washed 1 to 2 times with tap water to aid in the visualization and quantitation of plaques which
indicate viral infection.
5.4 Synthesis of diblock polymer, mPEG-PLA
The synthesis of mPEG-PLA diblock polymer occurs through ring-opening
polymerization of D,L-lactide which uses mPEG as an initiator and stannous octate as a catalyst.
Under a protective nitrogen atmosphere, 2 grams of mPEG, 1 gram of D, L-lactide and 100 µL
of stannous octate were mixed at 140 °C for 4 hours. Once refluxed, the product was purified by
dissolution in dichloromethane, precipitated in diethyl ether and then dried overnight. The final
product was then lyophilized (LABCONCO FreeZone 4.5 Plus) and then stored at -20°C until
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characterization on Fourier-transform infrared spectroscopy (Thermo Scientific Nicolet iS10) or
until further use.

5.5 Synthesis of mPEG-PLA Micelles
To synthesize blank micelles of mPEG-PLA, its previous lyophilized product was
dissolved in ultrapure DI water (18.2 MW cm at 25°C) at a ratio of 20 mg of polymer in 1 mL of
water and placed in a water bath (Thermo Scientific Precision CIR 19) at 37°C for 4 hours. Once
thermal induced self-assembly of the micelles is complete, the solution is filtered through a 0.2
µm syringe filter (Corning sterile syringe filter). The filtrate containing blank micelles is then
characterized using UV-Visual spectroscopy (Shimadzu UV-2600 UV-VIS Spectrophotometer)
and dynamic light scattering (Malvern Nano series NANO-ZS ZetaSizer) to ensure that the
micelles were fully formed.
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CHAPTER 6
RESULTS

6.1 Cell Culture Based Suppression of PY-LP-3, PY-LP-6 and PY-LP-12
All three of the named pyridazine derivatives underwent cell culture suppression assays.
Representative results were derived from viral titration via plaque assay. Plaque assays' ability to
accurately measure viral titers depends on a number of variables, including the selection of the
correct host cells, media and growth conditions for cellular and viral viability and a precise
estimation of the viral incubation period to allow enough time for distinct and countable plaque
formation.43 Table 4 provides information on the host cells, duration of the infection period with
Zika virus and the incubation time allowed for plaque formation.
PY-LP-3

PY-LP-6

PY-LP-12

Cell Type

Vero

Vero

Vero

Infection period

1hr

1hr

1hr

Incubation Time

3-5 days

5 days

5 days

Table 3: Cell type, infection period and incubation time of PY-LP-3, PY-LP-6 and PY-LP-12

After the initial infection and application of an immobilizing overlay which is
carboxymethyl cellulose (CMC), individual plaques will start to develop as viral infection and
replication are constrained to the surrounding monolayer. CMC allows plaques to form because
it greatly decreases viral spread. After incubation, cells are stained to enhance the contrast
between plaques and the uninfected monolayer. Plaques are then enumerated and used to
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calculate the titer of infectious virus in the specimen. When enumerated, plaques were distinct
and countable to the naked eye.
The following formula is used to determine virus titer:
Number of plaques x (D x V) = pfu/mL
D = dilution factor
V = Volume of diluted virus/well
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Figure 15: Control plate showcasing the effects of no virus/no drug infection and virus/no drug infection
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Figure 16: Vero cells were plated at 0.24 x 106 cells and infected with Zika virus using 10-fold serial
dilutions against pyridazine derivative, PY-LP-3. (MOI = 1.0). Plaques were counted and titered.
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Figure 17: Vero cells were plated at 0.24 x 106 cells and infected with Zika virus using 10-fold serial dilutions
against pyridazine derivative, PY-LP-6. (MOI = 1.0). Plaques were unable to counted and tittered for due to large
amount of cell death.
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Figure 18: Vero cells were plated at 0.24 x 106 cells and infected with Zika virus using 10-fold serial dilutions against pyridazine
derivative, PY-LP-12. (MOI = 1.0). Plaques were unable to counted and tittered for due to large amount of cell death.

6.2 Characterization of diblock polymer, mPEG-PLA
Fourier-transform infrared spectroscopy, or FTIR, was carried out on the AB diblock to
confirm proper diblock production (Figure 20). The two segments were verified by comparing
the FTIR peaks to values from the literature. The peak found around 2900 cm-1 is due to CH
stretching seen in the mPEG segments. The peak around 1750 cm-1 in the diblock polymer
reveals the existence of the esters in the PLA segment. Peaks at 1000 cm-1 in the fingerprint area
contributes to ether stretching. (Figure 19)

34

PLA

Figure 19: FT-IR analysis of methoxypolyethylene glycol (mPEG) and D,L-Lactide (PLA)

35

Figure 20: FT-IR analysis of complete diblock polymer, mPEG-PLA.

6.3 Characterization of diblock polymer, mPEG-PLA micelles
Due to a shortage of supply of pyridazine derivatives PY-LP-3, PY-LP-6 and PY-LP-12, ,
mPEG-PLA micelles were unable to be drug loaded. Therefore, after being thermally induced for
self-assembly and filtered, polymer based micelles without any drugs loaded into them, also
known as blanks were characterized via UV-visual spectroscopy and to ensure micelle
formation. Figure 19 shows the spectra of mPEG-PLA blanks where there is a distinct peak
occurring around 310 nm.
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Figure 21: UV-visual spectroscopy of mPEG-PLA blanks micelles suspended in ultra-pure DI water

As an initial assessment of co-polymer assembly into biodegradable micellar
nanoparticles, additional characterization of the blank micelles was carried out. Micelle surface
charge was determined using the zeta potential method, and the average diameter of each micelle
particle in suspension was determined using dynamic light scattering. These measurements were
used to predict strong repulsive or attractive forces that might arise when the micelles are tested
in vitro. The zeta potential of micelles is -1.44 mV (Figure 20) while the average diameter of the
micelles is 78.96 nm (Figure 21).
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Figure 22: Zeta potential of mPEG-PLA micelles suspended in ultra-pure DI water.
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Figure 23: Average diameter of mPEG-PLA micelles suspended in ultra-pure DI water determined by dynamic light
scattering
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6.4 Cell Culture Based Suppression of mPEG-PLA nanoparticles vs Zika Virus
mPEG-PLA nanoparticles were tested against Zika virus to account for any signs of viral
suppression from the copolymer alone. Viral suppression techniques include that of a dose
dependence assay along with viral titration via plaque assay. Visible plaques were seen which
indicated viral suppression.
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Figure 24: Vero cells were plated at 0.24 x 106 cells and infected with Zika virus using 10-fold serial dilutions
against mPEG-PLA nanoparticles
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CHAPTER 7
DISCUSSION

Cell culture refers to the process in which cells are grown under controlled conditions.
These conditions include temperature, pH, osmotic pressure oxygen and carbon dioxide levels.
The growth of cells in laboratories reap myriad benefits as they are used to diagnose infections,
test new drugs and play a fundamental role in research. Cell culture suppression techniques such
as dose dependance assays and viral titration via plaque assay are well accepted amongst the
scientific community as these assays provide fast-generating and reproducible results. With
pyridazine derivatives having advantageous physiochemical properties, its integration towards
the strategies and development of small molecule inhibitors and drug delivery systems against
viruses serves prime importance within research. 44
Pyridazine derivatives used for the purpose of this research each emphasized a unique
structural role as they differed in the attachment of various functional groups (-NH2, -Cl and
-OCH3) which attributed different effects on cell culture. Visualization of the effects was
showcased through viral titration via plaque assay which is a direct method for quantification.
All derivatives were added to cell plates that contained Vero Cells and 50 μL Zika Virus after
calculations of the working concentration of each derivative was done.
Data supports the successful suppression of Zika virus with the use of PY-LP-3 as seen in
Figure 15. Success is attributed to the amino functional group. Both PY-LP-6 and PY-LP-12
underwent a vast amount of cell death and were unable to be quantified via plaques. This could
have been attributed to the drug itself or the cell line in which we suspected could have been
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Dengue which previously had difficulties growing in cell culture. Some limitations of cell culture
suppression techniques include contamination and cell line misidentification.
It was necessary to first create a biocompatible polymer that could be shaped into a drug
carrier before synthesizing the pH-dependent micelles. mPEG-PLA, an AB, diblock polymer,
was created using a previously described procedure. The mPEG or polyetheylene glycol that
makes up the A monomer was joined to the polylactide that makes up the B monomer to create
the AB diblock to create the finished polymer. The polymer underwent characterization after
being synthesized to assure proper diblock formation. The complete AB diblock underwent
infrared spectroscopy using FTIR infrared spectroscopy.
In order to verify that the proper polymerization took place, the FTIR peaks and
distinctive fingerprint regions were compared to published values. The CH stretching present in
the mPEG segments is the cause of the peak at 2900 cm-1. The presence of esters in the PLA
segment is shown by the peak at 1750 cm-1 in the diblock polymer. The ether is stretched in part
by peaks at 1000 cm-1 in the fingerprint region. The distinctive FTIR spectra's comparison to
literature values allowed the polymer's identity—mPEG-PLA—to be verified.
With polymer successfully synthesized the next step was to pursue the synthesis of the
nanoparticles. The nanoparticle, drug delivery system used was a single layer micelle made from
a diblock polymer. Diblock, biodegradable micelles made from mPEG-PLA were synthesized
and characterized. The peak absorbance on the UV-vis spectra for the micelles was 310 nm while
the average diameter was 78.96 nm using dynamic light scattering. Due to the mPEG-PLA, not
being loaded with any drug, the core can exhibit weak intermolecular forces making
it unstable. This instability can be seen between the 300nm -400nm range where there are
several bumps. If the mPEG-PLA micelle was

Drug-loaded, the curve between this range
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would have been smoother and been slightly blue shifted (around 350nm). The average diameter
of the mPEG-PLA was 78.96. When compared to literature, this value is acceptable as the
average diameter of mPEG-PLA micelles are between 30nm to 100nm.
Due to shortage of the pyridazine derivatives, empty mPEG-PLA nanoparticles were used
in cell culture suppression assays to showcase whether or not the particles themselves showcase
suppression. This proved to be true as plaque assay of mPEG-PLA and Zika virus showcased
plaques which coincides with suppression.
The results noted lays the foundation for a viable drug delivery system that involves
novel antivirals encapsulated by biodegradable micellar nanoparticles that target dengue
virus and Zika virus with the ability to suppress these viruses.
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CHAPTER 8
CONCLUSION AND FUTURE OUTLOOK
The main objectives of this research are to create efficient antivirals, a responsive
biodegradable diblock, and nanoparticle drug delivery systems that would make it simple to
distribute medications inside the body. The information presented in this thesis research
demonstrates that efforts to develop antiviral Pyridazine derivatives and diblock polymers
against mosquito-borne viruses have been successful.
Future directives of this research call for core drug-load led mPEG-PLA nanoparticles
having a certain pH dissociation range, release time, and functionalization capability. Copolymer
micellar nanoparticles enhance antiviral drug delivery by increasing drug solubility by encasing
the drug molecule until it reaches the desired spot. The trans-Golgi network would be the
intended goal in this scenario. With ongoing characterization that includes use of the Zetasizer,
NMR and IR analysis, UV-spectroscopy, and microscopy, it is vital to test and examine viral
infection suppression capacities against mPEG-PLA blanks and drug-loaded micelles. Cell
culture suppression testing with capsuled and encapsulated should also be of utmost importance.
The lack of approved vaccines, medications and treatment regimens against dengue and
Zika virus calls for the critical need of antivirals. The possibilities of the biocompatible coblock
drug delivery system are not limited to mPEG-PLA and pyridazine derivatives, but rather a step
closer to the discovery of a successful solution towards Flavivirdae viruses.
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